St. Francis LLC v. MMP Capital, Inc.

CourtDistrict Court, E.D. New York
DecidedMarch 31, 2022
Docket2:20-cv-04636
StatusUnknown

This text of St. Francis LLC v. MMP Capital, Inc. (St. Francis LLC v. MMP Capital, Inc.) is published on Counsel Stack Legal Research, covering District Court, E.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
St. Francis LLC v. MMP Capital, Inc., (E.D.N.Y. 2022).

Opinion

UNITED STATES DISTRICT COURT EASTERN DISTRICT OF NEW YORK -------------------------------------------------------------- ST. FRANCIS HOLDINGS, LLC and FRANCIS J. AVERILL, M.D.,

Plaintiffs, MEMORANDUM & ORDER 20-CV-4636 (MKB) v.

MMP CAPITAL, INC.,

Defendant. -------------------------------------------------------------- MARGO K. BRODIE, United States District Judge: Plaintiffs St. Francis Holdings, LLC and Francis J. Averill, M.D. filed the above-captioned action on June 12, 2020, against Defendant MMP Capital, Inc. (“MMP”), alleging that (1) a sales agent acting on behalf of Defendant fraudulently induced Plaintiffs to enter into a finance agreement, (2) Defendant violated the Florida Deceptive and Unfair Trade Practices Act (the “FDUTPA”), (3) Plaintiffs canceled and/or rescinded the finance agreement, and (4) Defendant committed civil conspiracy.1 (Am. Compl. ¶¶ 94–105, 116–52, Docket Entry No. 21.) Plaintiffs allege that they executed a finance agreement with Defendant following a

1 Plaintiffs commenced the initial action on December 30, 2019 against Cynosure, LLC (“Cynosure”) in the Sixth Judicial Circuit of Florida, (Compl., annexed to Notice of Removal as Ex. B, Docket Entry No. 1-2), and Cynosure removed the case to the Middle District of Florida on May 12, 2020, (Notice of Removal, Docket Entry No. 1). On June 12, 2020, Plaintiffs filed an Amended Complaint asserting claims against Defendant, Cynosure, Pawnee Leasing Corp., and Amur Equipment Finance, Inc. (“Amur”). (Am. Compl., Docket Entry No. 21.) Defendant moved to transfer venue to the Eastern District of New York based on a forum-selection clause in the parties’ finance agreement. (Mot. to Change Venue, Docket Entry No. 55.) Judge William F. Jung of the Middle District of Florida granted Defendant’s motion and transferred the claims against Defendant and Amur to this Court. (Order dated Sept. 23, 2020, Docket Entry No. 81.) On February 10, 2022, Plaintiffs voluntarily dismissed their claims against Amur. (Notice of Voluntary Dismissal dated Feb. 10, 2022, Docket Entry No. 108.) “cold call[]” from a sales agent attempting to sell them on the idea of purchasing equipment to start a new aesthetics practice and a June 26, 2019 sales meeting, (id. at ¶¶ 35–36, 48), and further allege that the agent made a number of “inflated claims and material misrepresentations and omissions” concerning the efficacy and operation of the equipment, (id.at ¶¶ 37–44, 66, 75–

79). Plaintiffs seek rescission of the agreement and disgorgement of amounts paid to purchase the equipment. (Id. at ¶¶ 105, 130–39.) Defendant moves to dismiss the Amended Complaint for failure to state a claim pursuant to Rule 12(b)(6) of the Federal Rules of Civil Procedure and Plaintiffs oppose the motion.2 Plaintiffs also seek leave to further amend the Complaint.3 For the reasons explained below, the Court grants Defendant’s motion to dismiss in part and denies it in part. The Court grants Plaintiffs leave to file a second amended complaint. I. Background The Court assumes the truth of the factual allegations in the Amended Complaint for the purpose of deciding Defendant’s motion.

a. Factual background i. June 2019 “cold call” and agreements In or around June of 2019, Kristopher Huston, the Director of Sales Growth of Cynosure, LLC, (“Cynosure”), a manufacturer of aesthetic medical devices, “cold called” Plaintiffs’ office

2 (Def.’s Mot. to Dismiss (“Def.’s Mot.”), Docket Entry No. 100; Def.’s Mem. in Supp. of Def.’s Mot. (“Def.’s Mem.”), Docket Entry No. 100-2; Pls.’ Mem. in Opp’n to Def.’s Mot. (“Pls.’ Opp’n”), Docket Entry No. 104.)

3 (Pls.’ Mot. to File Second Am. Compl. (“Pls.’ Mot.), Docket Entry No. 103; Def.’s Reply to Pls.’ Opp’n. and Opp’n to Pls.’ Mot. (“Def.’s Reply and Opp’n”), Docket Entry No. 101.) seeking to sell Plaintiffs on the idea of establishing a new aesthetics practice.4 (Am. Compl. ¶¶ 4–6, 35.) Huston recommended that Plaintiffs purchase Cynosure’s (1) SculpSure Contouring Platform (“SculpSure System”) — a non-invasive body-contouring device that eliminates unwanted fat cells without surgery — and (2) TempSure Envi System (“TempSure System”) —

a device that purportedly reduces the appearance of wrinkles — for the new aesthetic practice. (Id. at ¶¶ 4, 33–35.) On June 26, 2019, Huston visited Plaintiffs’ office and conducted a presentation on the SculpSure and TempSure Systems. (Id. at ¶ 36.) Dr. Averill, a board-certified physician and managing member of St. Francis Holdings, LLC, attended the presentation. (Id. at ¶¶ 2, 36.) During the presentation, Huston described the SculpSure System as “virtually painless” for patients and claimed that the device could be used “hands free” or without a trained staff member present during most of the treatment. (Id. at ¶¶ 40–41, 95.) In addition to stating that the SculpSure and TempSure Systems were well-suited for a new aesthetics practice and likely to be highly profitable, (id. at ¶¶ 38–42), Huston also represented that Cynosure would provide

financing for the equipment, including a six-month payment deferral after signing, and a $26,750.00 “marketing rebate check” within six to eight weeks after purchase, (id. at ¶¶ 43–45). Based on Huston’s representations, Plaintiffs entered into four agreements to procure both systems. (Id. at ¶¶ 48–49.) First, they executed two purchase agreements with Cynosure— a purchase order for the SculpSure System and a purchase order for the TempSure System (the “Purchase Agreements”). (Id.; Purchase Agreements at 2–3, annexed to Am. Compl. as Ex. 4, Docket Entry No. 21.) Second, Plaintiffs signed a finance agreement contract with Defendant,

4 Plaintiffs already maintained a medical practice specializing in pulmonary care prior to Huston’s call; Plaintiffs did not offer aesthetic or cosmetic services. (Am. Compl. ¶ 38.) an equipment finance company, for the financing to procure the TempSure System (the “Finance Agreement”). (Am. Compl. ¶¶ 21, 48; Def.’s Mem. at 10.) Lastly, Plaintiffs signed an equipment leasing agreement with Pawnee Leasing Corp., (“Pawnee”), an equipment financing company, allowing St. Francis to lease the SculpSure System from Pawnee (the “Leasing

Agreement”). (Id. at ¶¶ 13, 16, 48; Def.’s Mem. at 1 n.1.) Huston presented the agreements to Plaintiffs predated and preprinted with Dr. Averill’s personal identifying information. (Id. at ¶ 48.) ii. The Purchase Agreements with Cynosure The Purchase Agreements list the SculpSure and TempSure Systems for $205,750 and $140,750, respectively. (Product Descriptions, Purchase Agreements at 2–3.) They also provide a $26,750 marketing rebate as a part of the purchase. (Id; Am. Compl. ¶ 44; Cynosure Letter dated Aug. 30, 2019 at 1, annexed to Am. Compl. as Ex. 12, Docket Entry No. 21.) However, in a letter Cynosure sent to Plaintiffs after Plaintiffs attempted to return the equipment, Cynosure stated that it was unable to amend the terms of the Leasing Agreement or the Finance Agreement

— or otherwise release Plaintiffs from their obligations thereunder — because it “is not a party to the [agreements].” (Cynosure Letter dated Aug. 30, 2019 at 1.) The Purchase Agreements promise “on-site installation” and “clinical in-service” to train Plaintiffs on how to utilize the SculpSure and TempSure Systems. (Product Descriptions, Purchase Agreements at 2–3; Am. Compl. ¶¶ 63–64.) They also limit cancellation of purchase, stating that “[a]ll [s]ales are final [and] Cynosure [g]rants no right of return.” (Purchase Agreements at 1; Cynosure Letter dated Aug. 30, 2019 at 1.) iii.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Philip A. Zlotnick v. Premier Sales Group, Inc.
480 F.3d 1281 (Eleventh Circuit, 2007)
Ferens v. John Deere Co.
494 U.S. 516 (Supreme Court, 1990)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Steinbeck v. Steinbeck Heritage Foundation
400 F. App'x 572 (Second Circuit, 2010)
Matson v. BD. OF EDUC., CITY SCHOOL DIST. OF NY
631 F.3d 57 (Second Circuit, 2011)
James G. Neal v. Hardee's Food Systems, Inc.
918 F.2d 34 (Fifth Circuit, 1990)
Bigio v. Coca-Cola Co.
675 F.3d 163 (Second Circuit, 2012)
Krock v. Lipsay
97 F.3d 640 (Second Circuit, 1996)
Let W. Lee v. Bankers Trust Company
166 F.3d 540 (Second Circuit, 1999)
Dinaco, Inc. v. Time Warner, Inc.
346 F.3d 64 (Second Circuit, 2003)
Torres v. Walker
356 F.3d 238 (Second Circuit, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
St. Francis LLC v. MMP Capital, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/st-francis-llc-v-mmp-capital-inc-nyed-2022.